Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 13;6(2):5389.
doi: 10.4081/rt.2014.5389. eCollection 2014 May 13.

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

Aibek E Mirrakhimov  1 , Alaa M Ali  1 , Maliha Khan  1 , Aram Barbaryan  1
Affiliations
Review

Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature

Aibek E Mirrakhimov et al. Rare Tumors. .

Abstract

Tumor lysis syndrome (TLS) is a potentially deadly complication of tumors or their treatment. This syndrome consists of a constellation of laboratory findings such as hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, known as laboratory TLS. When clinical complications such as seizures, acute renal failure, and cardiac dysrhythmias occur in patients with laboratory TLS, the syndrome is called clinical TLS. TLS is especially common in patients with hematological malignancies with rapid cellular turnover rates such as acute lymphocytic leukemia and Burkitt lymphoma, but is very rare in patients with solid tumors. Nevertheless, there are multiple reports in the literature on the occurrence of TLS in patients with solid tumors. In this review article, we summarize the current data on the occurrence of TLS in patients with solid tumors. We propose an algorithm of risk stratification and prevention of TLS in patients with solid cancers.

Keywords: solid cancers; tumor lysis syndrome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests: the authors declare no potential conflict of interests.

Figures

Figure 1.
Figure 1.
Proposed evaluation for the risk of tumor lysis syndrome and its prevention among patients with solid tumors.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Deaths: preliminary data for 2011. Available from:http://www.cdc.gov/nchs/data/ nvsr/nvsr61/nvsr61_06.pdf - PubMed
    1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11 - PubMed
    1. Wilson FP, Berns JS. Onco-nephrology: tumor lysis syndrome. Clin J Am Soc Nephrol 20127:1730–9 - PubMed
    1. Will A, Tholouli E. The clinical management of tumour lysis syndrome in haematological malignancies. Br J Haematol. 2011;154:3–13 - PubMed
    1. Mika D, Ahmad S, Guruvayoorappan C. Tumour lysis syndrome: implications for cancer therapy. Asian Pac J Cancer Prev. 2012;13:3555–60 - PubMed

LinkOut - more resources